✉news BusinessRetail first seen 6 h ago, last 58 min ago, peak #6

ImmunityBio Shares Post Best Week In Months On Trump Cancer Panel Pick

Original: IBRX Stock Logs Best Week In Over 7 Months: Retail Eyes Anktiva Boost From Trump’s Cancer Panel Pick

ImmunityBio stock (IBRX) wrapped up its strongest week in more than seven months as retail investors bet its bladder cancer drug Anktiva could benefit from the Trump administration's choice to lead a cancer-focused advisory panel. Traders are speculating the pick could speed adoption or funding for Anktiva, driving renewed buying interest in the biotech.

Why now: The White House cancer panel appointment has sparked retail speculation that ImmunityBio's Anktiva could gain policy backing, lifting the stock sharply this week.

ImmunityBioAnktivaDonald TrumpIBRX

Open on news →

Rank over time, top of the chart is #1. 5 snapshots from 6 h ago to 58 min ago.

Evidence

• IBRX Stock Logs Best Week In Over 7 Months: Retail Eyes Anktiva Boost From Trump’s Cancer Panel Pick · TradingView
• IBRX Stock Logs Best Week In Over 7 Months: Retail Eyes Anktiva Boost From Trump’s Cancer Panel Pick · Stocktwits

API: https://socialmediatrends-api.osmike.com/v1/trends/1057495